
Graham Dark

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10770756/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2022, 23, 919-930.	10.7	11
2	Objective responses to first-line neoadjuvant carboplatin–paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology, The, 2021, 22, 277-288.	10.7	34
3	Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology, The, 2020, 21, 969-977.	10.7	23
4	Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet, The, 2019, 394, 2084-2095.	13.7	142
5	An Association of Cancer Physicians' strategy for improving services and outcomes for cancer patients. Ecancermedicalscience, 2016, 10, 608.	1.1	5
6	Single-Agent Pemetrexed for ChemonaÃ ⁻ ve and Pretreated Patients with Malignant Pleural Mesothelioma: Results of an International Expanded Access Program. Journal of Thoracic Oncology, 2008, 3, 764-771.	1.1	59
7	C5-03: Open-label study of pemetrexed alone or in combination with a platinum for previously treated patients (pts) with malignant pleural mesothelioma (MPM): Outcomes from the International Expanded Access Program (EAP). Journal of Thoracic Oncology, 2007, 2, S372-S373.	1.1	6
8	Recent advances in mesothelioma. Clinical Medicine, 2003, 3, 314-317.	1.9	2